Literature DB >> 11355345

Aptamers as reagents for high-throughput screening.

L S Green1, C Bell, N Janjic.   

Abstract

The identification of new drug candidates from chemical libraries is a major component of discovery research in many pharmaceutical companies. Given the large size of many conventional and combinatorial libraries and the rapid increase in the number of possible therapeutic targets, the speed with which efficient high-throughput screening (HTS) assays can be developed can be a rate-limiting step in the discovery process. We show here that aptamers, nucleic acids that bind other molecules with high affinity, can be used as versatile reagents in competition binding HTS assays to identify and optimize small-molecule ligands to protein targets. To illustrate this application, we have used labeled aptamers to platelet-derived growth factor B-chain and wheat germ agglutinin to screen two sets of potential small-molecule ligands. In both cases, binding affinities of all ligands tested (small molecules and aptamers) were strongly correlated with their inhibitory potencies in functional assays. The major advantages of using aptamers in HTS assays are speed of aptamer identification, high affinity of aptamers for protein targets, relatively large aptamer-protein interaction surfaces, and compatibility with various labeling/detection strategies. Aptamers may be particularly useful in HTS assays with protein targets that have no known binding partners such as orphan receptors. Since aptamers that bind to proteins are often specific and potent antagonists of protein function, the use of aptamers for target validation can be coupled with their subsequent use in HTS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11355345     DOI: 10.2144/01305dd02

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  8 in total

Review 1.  A review on emerging diagnostic assay for viral detection: the case of avian influenza virus.

Authors:  Taha Roodbar Shojaei; Meisam Tabatabaei; Sherif Shawky; Mohamad Amran Mohd Salleh; Dirk Bald
Journal:  Mol Biol Rep       Date:  2014-09-23       Impact factor: 2.316

Review 2.  Aptamer-based targeted therapy.

Authors:  Guizhi Zhu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-08-17       Impact factor: 15.470

Review 3.  Aptamer-Drug Conjugates.

Authors:  Guizhi Zhu; Gang Niu; Xiaoyuan Chen
Journal:  Bioconjug Chem       Date:  2015-07-14       Impact factor: 4.774

4.  Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology.

Authors:  Cleber A Trujillo; Arthur A Nery; Janaína M Alves; Antonio H Martins; Henning Ulrich
Journal:  Clin Ophthalmol       Date:  2007-12

Review 5.  Nucleic acid aptamers: an emerging frontier in cancer therapy.

Authors:  Guizhi Zhu; Mao Ye; Michael J Donovan; Erqun Song; Zilong Zhao; Weihong Tan
Journal:  Chem Commun (Camb)       Date:  2012-11-04       Impact factor: 6.222

6.  Commentary on aptamers for virus research.

Authors:  Yasuyuki Miyazaki; Mikako Fujita
Journal:  Front Microbiol       Date:  2012-02-14       Impact factor: 5.640

7.  CELL-SELEX: Novel perspectives of aptamer-based therapeutics.

Authors:  Ke-Tai Guo; Gerhard Ziemer; Angela Paul; Hans P Wendel
Journal:  Int J Mol Sci       Date:  2008-04-24       Impact factor: 6.208

8.  Integrated Microfluidic Isolation of Aptamers Using Electrophoretic Oligonucleotide Manipulation.

Authors:  Jinho Kim; Timothy R Olsen; Jing Zhu; John P Hilton; Kyung-Ae Yang; Renjun Pei; Milan N Stojanovic; Qiao Lin
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.